Adequan - AQHA

Adequan® i.m. (polysulfated glycosaminoglycan)

Official Equine Joint Therapy Manufacturer of AQHA and An Official Animal Health Care Manufacturer of AQHA

text size

Mobility is longevity: Focused on keeping horses performing at every stage of life.

American Regent Animal Health is dedicated to advancing joint care for horses with FDA-approved products, including Adequan® i.m. We are also passionate supporters of the AQHA, an association that shares our commitment to the health and well-being of horses through education, expertise and valuable member resources.

First of its kind. Still one of a kind.

Adequan® i.m. is like no other equine drug product available. After 30 years, it’s still the only FDA-approved equine intramuscular treatment for non-infectious degenerative joint disease (DJD) of the carpal and hock joints.

Start early to help your horse keep moving and performing.

Since joint damage can escalate, it’s important to catch the signs early and minimize progression of the disease. Many products are available to help reduce pain and inflammation or improve mobility, including NSAIDs and supplements. But Adequan® i.m. is the only PSGAG treatment that proactively treats the disease and not just the signs of DJD.^1,2

Reaches joints quickly. Helps improve mobility.

Adequan® i.m. not only reaches joints quickly, but also helps protect and improve joint mobility. Proven to work in multiple ways to:^1,2

• Reduce inflammation

• Restore synovial joint lubrication

• Repair joint cartilage

• Reverse the disease cycle

Clinical significance of the above results is unknown.

When you start and stay with Adequan® i.m.,horses may enjoy greater mobility over a lifetime.^1,2,3

Discover if Adequan is the right choice for your horse. Visit www.adequan.com and www.aranimalhealth.com.

Adequan® i.m.
Brand of Polysulfated Glycosaminoglycan (PSGAG)

INDICATIONS
Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

IMPORTANT SAFETY INFORMATION
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For full prescribing information, click here.

1. Adequan® i.m. Package Insert, Rev 1/19

2. Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycanin equine body fluid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703.

3. Kim DY, Taylor HW, Moore RM, Paulsen DB, Cho DY. Articular chondrocyte apoptosis in equine osteoarthritis. The Veterinary Journal 2003; 166: 52-57.